XM无法为美国居民提供服务。

Pot stocks fall as US DEA pushes cannabis reclassification hearing to December



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>Pot stocks fall as US DEA pushes cannabis reclassification hearing to December</title></head><body>

Aug 27 (Reuters) -Shares of cannabis companies sank on Tuesday after the U.S. Drug Enforcement Administration (DEA) postponed its cannabis reclassification hearing to Dec. 2, after the U.S. presidential election.

The Department of Justice, which oversees the DEA, said Attorney General Merrick Garland recommended cannabis be reclassified as a Schedule three drug instead of Schedule one earlier this year. Schedule one is reserved for drugs with a high potential for abuse and no accepted medical use.

Shares of Curaleaf CURA.TO and U.S.-listed shares of Canopy Growth CGC.O fell over 10%, while Illinois-based Verano Holdings VRNO.NLB was down 12.9%.

The AdvisorShares Pure US Cannabis ETF dipped 9.1%, having fallen as much as 12% earlier in the session.

Canada-listed Green Thumb Industries GTII.CD, Tilray Brands TLRY.TO, and Trulieve Cannabis TRUL.CD were down 8.6%, 6% and 5% respectively.

"We believe both candidates are likely to let rescheduling advance, though we have more confidence in Kamala Harris than in Donald Trump," said analysts at TD Cowen in a note.

Analysts also noted that the outcome would heavily depend on Trump's choice for key positions such as Attorney General, the director of the DEA, and the Secretary of Health and Human Services, should he win.

The HHS' National Survey on Drug Use and Health for 2023 showed that marijuana is the most commonly used illicit drug, with 21.8% of people aged 12 or older, or 61.8 million people, reporting use.

Reclassifying marijuana would represent a first step toward narrowing the wide policy chasm between state and federal cannabis laws.

Medical cannabis is legal in 38 states and various U.S. territories, while recreational use is permitted in 24 states and Washington, D.C.; however, it remains federally illegal.

Until then, "the extended wait for rescheduling decisions could maintain the status quo, leaving businesses to navigate a patchwork of state regulations and ongoing federal ambiguity," said Pete Sahani chief executive officer of the cannabis hardware firm, the Blinc Group.



Reporting by Seher Dareen in Bengaluru; Editing by Tasim Zahid

</body></html>

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明